# Tenon Medical, Inc.: overview TNON · Nasdaq · CIK 1560293 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tnon.md) · [Financials](/companies/tnon/financials.md) · [Filings](/companies/tnon/filings.md) · [Insiders](/companies/tnon/insiders.md) Latest reported revenue: [$1.3m](/filings/0001213900-26-089258.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-089258). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [887](/filings/0001213900-25-109961.md) | [770 d](/filings/0001213900-26-035707.md) | [726](/filings/0001213900-26-057695.md) | [564](/filings/0001213900-26-089258.md) | [1,173](/filings/0001213900-25-109961.md) | [1,481 d](/filings/0001213900-26-035707.md) | [1,379](/filings/0001213900-26-057695.md) | [1,279](/filings/0001213900-26-089258.md) | | Gross margin | % | [47.1%](/filings/0001213900-25-109961.md) | [45.8% d](/filings/0001213900-26-035707.md) | [44.5%](/filings/0001213900-26-057695.md) | [43.4%](/filings/0001213900-26-089258.md) | [65.9%](/filings/0001213900-25-109961.md) | [68.7% d](/filings/0001213900-26-035707.md) | [68.5%](/filings/0001213900-26-057695.md) | [63.6%](/filings/0001213900-26-089258.md) | | Operating margin | % | [(362.5%)](/filings/0001213900-25-109961.md) | [(412.1%) d](/filings/0001213900-26-035707.md) | [(506.5%)](/filings/0001213900-26-057695.md) | [(506.6%)](/filings/0001213900-26-089258.md) | [(289.2%)](/filings/0001213900-25-109961.md) | [(193.5%) d](/filings/0001213900-26-035707.md) | [(237.9%)](/filings/0001213900-26-057695.md) | [(262.2%)](/filings/0001213900-26-089258.md) | | Net margin | % | [(359.0%)](/filings/0001213900-25-109961.md) | [(400.9%) d](/filings/0001213900-26-035707.md) | [(498.1%)](/filings/0001213900-26-057695.md) | [(491.0%)](/filings/0001213900-26-089258.md) | [(284.7%)](/filings/0001213900-25-109961.md) | [(191.2%) d](/filings/0001213900-26-035707.md) | [(252.1%)](/filings/0001213900-26-057695.md) | [(316.7%)](/filings/0001213900-26-089258.md) | | Diluted EPS | $ per share | [(3.63)](/filings/0001213900-25-109961.md) | not reported | [1.01](/filings/0001213900-26-057695.md) | [(12.76)](/filings/0001213900-26-089258.md) | [(0.40)](/filings/0001213900-25-109961.md) | not reported | [0.31](/filings/0001213900-26-057695.md) | [(12.35)](/filings/0001213900-26-089258.md) | | Free cash flow | $k | [(2,447) d](/filings/0001213900-25-109961.md) | [(2,814) d](/filings/0001213900-26-035707.md) | not reported | not reported | [(3,935) d](/filings/0001213900-25-109961.md) | [(2,416) d](/filings/0001213900-26-035707.md) | [(3,016)](/filings/0001213900-26-057695.md) | [(2,930) d](/filings/0001213900-26-089258.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.2](/filings/0001575872-23-000346.md) | [0.7](/filings/0001213900-24-028010.md) | [2.9](/filings/0001013762-25-002734.md) | [3.3](/filings/0001213900-26-035707.md) | [3.9](/filings/0001213900-26-035707.md) | | Gross margin | % | [65.6%](/filings/0001575872-23-000346.md) | [(92.8%)](/filings/0001213900-24-028010.md) | [42.4%](/filings/0001013762-25-002734.md) | [52.2%](/filings/0001213900-26-035707.md) | [59.8%](/filings/0001213900-26-035707.md) | | Operating margin | % | [(4038.1%)](/filings/0001575872-23-000346.md) | [(2709.8%)](/filings/0001213900-24-028010.md) | [(537.1%)](/filings/0001013762-25-002734.md) | [(420.1%)](/filings/0001213900-26-035707.md) | [(324.3%)](/filings/0001213900-26-035707.md) | | Net margin | % | [(4405.0%)](/filings/0001575872-23-000346.md) | [(2737.6%)](/filings/0001213900-24-028010.md) | [(532.1%)](/filings/0001013762-25-002734.md) | [(417.2%)](/filings/0001213900-26-035707.md) | [(318.4%)](/filings/0001213900-26-035707.md) | | Diluted EPS | $ per share | [(7.81)](/filings/0001575872-23-000346.md) | [(23.62)](/filings/0001213900-24-028010.md) | [(68.64)](/filings/0001013762-25-002734.md) | [(11.26)](/filings/0001213900-26-035707.md) | [(1.70)](/filings/0001213900-26-035707.md) | | Free cash flow | $m | [(4.4)](/filings/0001575872-23-000346.md) | [(12.9)](/filings/0001213900-24-028010.md) | [(12.5)](/filings/0001013762-25-002734.md) | [(10.1)](/filings/0001213900-26-035707.md) | [(11.0)](/filings/0001213900-26-035707.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tnon/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Focus Partners Wealth](/funds/1542153.md) | 2026-06-30 | $51.0k | 4,720,000 | | Added +4,658,113 | | [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $10.3k | 952,794 | | Reduced −100 | | [Spectrum Asset Management, Inc. (NB/CA)](/funds/1632078.md) | 2026-06-30 | $7.3k | 679,420 | | Unchanged | | [HEIGHTS CAPITAL MANAGEMENT, INC](/funds/1081698.md) | 2026-06-30 | $1.5k | 140,236 | | Unchanged | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $1.4k | 131,000 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $839 | 70,499 | | Reduced −2,222 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $240 | 22,250 | | Unchanged | | [GTS SECURITIES LLC](/funds/1452765.md) | 2026-06-30 | $231 | 21,044 | | Reduced −100 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $5 | 499 | | Added +399 | ## Recent filings [All 300 filings](/companies/tnon/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 21:02 ET | [8-K](/filings/0001213900-26-111740.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-111740 | | 2026-09-16 | 21:23 ET | [8-K](/filings/0001213900-26-100596.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-100596 | | 2026-09-09 | 12:45 ET | [8-K](/filings/0001213900-26-098232.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-098232 | | 2026-08-31 | 19:40 ET | [8-K](/filings/0001213900-26-095686.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-095686 | | 2026-08-26 | 19:30 ET | [8-K/A](/filings/0001213900-26-093926.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-093926 | | 2026-08-24 | 17:23 ET | [8-K](/filings/0001213900-26-092944.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-092944 | | 2026-08-13 | 21:20 ET | [10-Q](/filings/0001213900-26-089258.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089258 | | 2026-08-13 | 20:25 ET | [8-K](/filings/0001213900-26-089138.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-089138 | | 2026-08-10 | 21:26 ET | [8-K](/filings/0001213900-26-087352.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-087352 | | 2026-07-24 | 20:45 ET | [8-K](/filings/0001213900-26-081438.md) | 5.07 Shareholder vote results | 0001213900-26-081438 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-035707.md), filed Mar 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/4875b78f-e5e5-429f-949a-2d6a7a874eb4) ## About the filer - CIK: 1560293 - Tickers: TNON, TNONW - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.